This trial is a critical step to uncovering an effective way to alleviate the seizure burden in this population of children with a rare, difficult-to-treat disease.
Tilray is supplying pharmacies around Croatia with orally administered medical cannabis products through a partnership with the Croatian Institute of Immunology.
Tilray is providing a proprietary capsule formulation for the proposed trial, which will allow researchers to trial an investigational product containing two active ingredients extracted from the cannabis plant.